

**Supplementary Figure 1.**

The simulated and observed relative risk for colorectal cancer (compared to average risk individuals) and cumulative colorectal cancer incidence rates among Hodgkin Lymphoma (HL) survivors per age and follow-up years since primary cancer diagnosis. This data is shown for the three different HL subgroups (entire cohort (A), treated with procarbazine without infradiaphragmatic radiotherapy (IRT, B) and treated with IRT and procarbazine (C). Model assumptions were tested with external data from Holmqvist et al. (2019). Simulated outcomes were computed assuming no surveillance.